Multiple sclerosis

RESEARCH PAPER

Characterising aggressive multiple sclerosis

Suresh Menon, 1 Afsaneh Shirani, 2 Yinshan Zhao, 3 Joel Oger, 2 Anthony Traboulsee, 1 Mark S Freedman, 4 Helen Tremlett 2

ABSTRACT

Objective To explore the occurrence and characteristics of aggressive multiple sclerosis (AMS) in adult-onset multiple sclerosis (MS) patients.

Methods Prospectively collected data (1980–2009) from British Columbia, Canada, were retrospectively analysed. AMS was defined in three different ways: (AMS1, 2 and 3): ‘AMS1’—confirmed Expanded Disability Status Scale (EDSS) ≥6 within 5 years of MS onset; ‘AMS2’—confirmed EDSS ≥6 by age 40; and ‘AMS3’—secondary progressive MS within 3 years of a relapsing-onset course. Three respective ‘non-aggressive’ MS comparison cohorts were selected. Patients’ characteristics were compared between aggressive and non-aggressive cohorts using multivariable logistic regression, with findings expressed as adjusted OR (AOR) and 95% CI.

Results Application of the three definitions to the source population of 5891 patients resulted in 235/4285 (5.5%) patients fulfilling criteria for AMS1 (59.6% were female; 74.3% had relapsing-onset MS); 388/2762 (14.0%) for AMS2 (65.2% were female; 92.8% had relapsing-onset MS) and 195/4918 (4.0%) patients for AMS3 (61.0% were female). Compared to the respective control cohorts, those with AMS were more likely to be male (AOR=1.5, 95% CI 1.1 to 2.0 (AMS1); 1.6, 95% CI 1.3 to 2.1 (AMS2); 1.8, 95% CI 1.3 to 2.4 (AMS3)), older at MS symptom onset (AOR=1.1; 95% CI 1.1 to 1.1 (AMS1 and AMS3)) and have primary progressive MS (AOR=2.3, 95% CI 1.6 to 3.3 (AMS1); 2.7, 95% CI 1.7 to 4.4 (AMS2)).

Conclusions AMS was identified in 4–14% of patients, depending on the definition used. Although there was a relative preponderance of men and primary progressive MS presenting with AMS, the majority of patients were still women and those with relapsing-onset MS.

INTRODUCTION

Multiple sclerosis (MS) is a common cause of neurological disability in young adults, 1 although the actual rate of progression and disability accumulation varies considerably. Rapid progression represents one extreme of the disease, referred to by some as ‘aggressive’ 2–9 or ‘malignant’10–12 MS. However, despite this being the most challenging disease course to deal with, there is no consensus or broadly accepted terminology or definition. The most widely used consensus criteria describing the disease phases in MS only provide a broad descriptive definition of ‘malignant’ MS as a “disease with a rapid progressive course, leading to significant disability in multiple neurologic systems or death in a relatively short time after disease onset”. 13 Consequently, very little is known about the prevalence or incidence of this extreme phenotype, and despite its potentially serious consequences, it is rarely explicitly examined in large population-based studies.

The absence of a population-based definition also represents an important unmet need with regard to evaluation of possible treatments for aggressive MS (AMS). In today’s age of highly active immunosuppressive drug therapy and stem cell transplantation, defining and understanding the epidemiology of AMS is a fundamental, important first step. We have purposely avoided the term ‘malignant’ MS to avoid confusion with the distinct ‘fulminant’ Marburg’s variant of MS, which is characterised by a severe monophasic illness with little recovery leading to death in a short time.13–20

We set out to explore the much needed criteria for AMS and to examine the characteristics of these patients by accessing a large longitudinal population-based data set in British Columbia, Canada. The main goal was to identify and describe patients with AMS by means of three different, explicit, clearly defined and unambiguous criteria for AMS that could be used by others. Here, we report on the demographic and clinical characteristics of these three groups with AMS. In addition, as a secondary aim we investigated how these three criteria broadly performed in terms of identifying AMS by comparing disease progression between the three groups after the definition of AMS had been reached.

METHODS

Study design and setting

Prospectively collected data from the British Columbia MS (BCMS) database were retrospectively analysed. The BCMS database was established in 1980 and is a population-based longitudinal database covering all four MS clinics (Vancouver, Victoria, Kelowna and Prince George) in the province of British Columbia, Canada (until the end of 2004 after which not all four clinics were linked). The database is estimated to capture about 80% of the MS population in British Columbia. At the first clinic visit, a detailed clinical history, supported by physical examination, is collected prospectively at each neurologist–patient encounter, typically on an annual basis, although more frequent visits could occur.

Patient selection

We included patients with adult-onset (≥18 years), definite MS (Poser23 or McDonald criteria24), who
were enrolled in the database from 1980 to 2009. Patients without an EDSS score were excluded. Disease course at onset was classified clinically into either a primary progressive (PP) or relapsing-onset (RO) course. The onset of secondary progressive multiple sclerosis (SPMS) was assigned by the treating neurologist, as in previous studies, and concurred with the definition outlined by Lublin and Reingold in 1996, although these guidelines were not published until after the database was established.

**Defining AMS and the control cohorts**

We explored three different definitions for AMS (AMS1, 2 and 3): ‘AMS1’—reached confirmed EDSS 6 or greater within 5 years from the onset of MS symptoms; ‘AMS2’—reached confirmed EDSS 6 or greater by age 40; and ‘AMS3’—reached SPMS within 3 years of a RO course (primary progressive multiple sclerosis (PPMS) patients were excluded). In addition, a combined cohort of patients who satisfied at least one of the EDSS-based criteria for AMS (ie, AMS1 or 2) was also considered. Confirmation of EDSS was achieved when a subsequent EDSS score ≥6, at least 150 days later but within 5 years of the first recorded EDSS ≥6, was recorded. Three comparison cohorts of patients without AMS (C1, 2 and 3) were selected as follows: ‘C1’ comprised patients known not to have reached EDSS 6 within 5 years from the onset of MS symptoms; ‘C2’ consisted of patients known not to have reached EDSS 6 or greater by age 40 years with the onset of MS symptoms between 18 and 40 years of age; and ‘C3’ included patients known not to have reached SPMS within 3 years of a RO course. The comparator cohort for the combined cohort of patients who satisfied at least one of the EDSS-based criteria for AMS (AMS1+AMS2) comprised of patients who were known not to have reached an EDSS 6 within 5 years from the onset of MS symptoms or by age 40 years (both criteria had to be fulfilled).

Care was taken when selecting cases and controls to ensure that a potential case could not be included as a control and vice versa. For instance, for the comparator cohorts, the definitions were created to ensure that patients had sufficient time and opportunity to be considered as having AMS before being selected as controls. In addition, patients first seen in the clinic beyond 5 years from symptoms onset with an EDSS ≥6 were not considered eligible for criterion AMS1 (or as a corresponding control, C1) as their EDSS status in the first 5 years was unknown. Similarly patients who were first seen in the clinic after 40 years of age with an EDSS ≥6 were not considered eligible for criterion AMS2 or C2 since the EDSS status by age 40 years was unknown. To prevent potential selection bias, patients exposed to a disease-modifying drug (DMD) were not excluded; instead DMD use was described for the different cohorts.

**Statistical analyses**

Characteristics of the aggressive and non-aggressive cohorts were initially compared using the χ² test for sex and disease course (RO vs PP) and the t test for age at MS onset. Multivariable analysis was performed using forward stepwise logistic regression with onset age, sex and disease course (RO vs PP) as covariates (where appropriate) and AMS status (yes, no) as the outcome. Findings were expressed as adjusted OR (AOR) with corresponding 95% CI.

**Sensitivity analysis**

We also performed a sensitivity analysis (primarily aimed at AMS1) to test whether we inadvertently excluded patients who may have had AMS (as defined by AMS1) but came to the clinic late (ie, after the 5-year window), by extending the time to the first EDSS 6 from 5 to 8 years. The characteristics of this extended cohort were compared with those of a corresponding comparator cohort, that is, those who had not reached EDSS 6 after 8 years of disease duration.

**Time to EDSS 8**

In order to ascertain whether the identified AMS patients continued to broadly represent AMS once the criteria were reached, we investigated subsequent disease progression by estimating the time to EDSS 8 from the first EDSS score of ≥6 using Kaplan-Meier survival curves. The survival times for each of the three AMS cohorts—AMS1, AMS2 and AMS3—were reported. Because of very high rates of right censoring in the comparator cohorts, whom by definition did not contain any patients with AMS, time to EDSS 8 in these cohorts was not investigated.

Statistical analyses were performed using the Predictive Analytics Software (PASW) Statistics V18.0 (SPSS Inc., Chicago, Illinois, USA).

**RESULTS**

Overall, 5891 patients with definite adult-onset MS with at least one recorded EDSS score were extracted from the BCMS database; their characteristics are shown in table 1. In all, 297 patients were excluded from the study because they had no recorded EDSS scores. Those excluded were similar to those included with respect to sex (males=83/297, 28.6% vs 1646/5891, 27.9%, p=0.78). However, excluded patients were older at onset (35.2±10.8 vs 33.4±9.6 years, p<0.01) and more likely to have PPMS (41/297, 13.8% vs 589/5891, 10.0%, p=0.03).

From the source population of 5891 patients, those fulfilling criteria for AMS (AMS1, 2 and 3) and the corresponding comparator cohorts (C1, 2 and 3) were selected and are described in table 2. While selecting patients for criterion AMS1 and the comparator cohort C1, 810 patients were not considered as they first came to clinic more than 5 years after the onset of symptoms and already had an EDSS score of 6 or greater. They were similar to the source population in terms of onset age (33.1±10.2 vs 33.4±9.6 years, p=0.41), but were more likely to be male (258/810, 31.9% vs 1646/5891, 27.9%, p<0.01) and have PPMS (192/810, 23.7% vs 589/5891, 10.0%, p<0.01). Similarly, while selecting patients for criterion AMS2 and the comparator cohort C2, 786 patients were not included with respect to sex (males=85/297, 28.6% vs 1646/5891, 27.9%, p=0.78). However, excluded patients were older at onset (35.2±10.8 vs 33.4±9.6 years, p<0.01) and more likely to have PPMS (41/297, 13.8% vs 589/5891, 10.0%, p=0.03).

**Table 1** Characteristics of the source multiple sclerosis population, British Columbia, Canada

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total population, number</td>
<td>5891</td>
</tr>
<tr>
<td>Sex, number (%)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>1646 (27.9)</td>
</tr>
<tr>
<td>Female</td>
<td>4245 (72.1)</td>
</tr>
<tr>
<td>Disease course, number (%)</td>
<td></td>
</tr>
<tr>
<td>Primary progressive MS</td>
<td>589 (10.0)</td>
</tr>
<tr>
<td>Relapsing-onset MS</td>
<td>5302 (90.0)</td>
</tr>
<tr>
<td>Age at symptom onset, years</td>
<td></td>
</tr>
<tr>
<td>Mean±SD</td>
<td>33.4 (9.57)</td>
</tr>
<tr>
<td>Range</td>
<td>18.0–75.2</td>
</tr>
</tbody>
</table>

MS, multiple sclerosis.
### Table 2  Patient characteristics of those fulfilling the different criteria for aggressive multiple sclerosis (AMS 1, 2 and 3) and the non-aggressive comparator cohorts (C1, 2 and 3)

<table>
<thead>
<tr>
<th></th>
<th>Aggressive MS</th>
<th>Comparator cohorts (non-aggressive MS)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AMS1 n/N=235/4285 (5.5%)</td>
<td>AMS2 n/N=388/2762 (14.0%)</td>
</tr>
<tr>
<td><strong>Sex: n (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males</td>
<td>95 (40.4)</td>
<td>135 (34.8)</td>
</tr>
<tr>
<td>Females</td>
<td>140 (59.6)</td>
<td>253 (65.2)</td>
</tr>
<tr>
<td>Unadjusted p value†</td>
<td>&lt;0.0001‡</td>
<td>&lt;0.0001§</td>
</tr>
<tr>
<td>Adjusted p value</td>
<td>&lt;0.0001*</td>
<td>&lt;0.0001*</td>
</tr>
<tr>
<td><strong>Disease course</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary progressive MS</td>
<td>60 (25.5)</td>
<td>28 (7.2)</td>
</tr>
<tr>
<td>Relapsing-onset MS</td>
<td>175 (74.5)</td>
<td>360 (92.8)</td>
</tr>
<tr>
<td>Unadjusted p value†</td>
<td>&lt;0.0001‡</td>
<td>&lt;0.0001§</td>
</tr>
<tr>
<td>Adjusted p value</td>
<td>&lt;0.0001*</td>
<td>&lt;0.0001*</td>
</tr>
<tr>
<td><strong>Age at symptom onset (years)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean±SD</td>
<td>39.8 (11.51)</td>
<td>25.6 (4.68)</td>
</tr>
<tr>
<td>Range</td>
<td>19.1–71.5</td>
<td>18.0–37.3</td>
</tr>
<tr>
<td>Unadjusted p value‡‡</td>
<td>0.0001‡‡</td>
<td>0.0001§‡‡</td>
</tr>
<tr>
<td>Adjusted p value</td>
<td>&lt;0.0001*</td>
<td>&lt;0.0001*</td>
</tr>
<tr>
<td><strong>Patients exposed to a DMD (at anytime)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>n (%)</td>
<td>98 (41.7)</td>
<td>148 (38.1)</td>
</tr>
</tbody>
</table>

*p Value obtained from multivariable logistic regression analysis adjusted for sex, disease course and onset age.
**p Value obtained from multivariable logistic regression analysis adjusted for sex and onset age.
†χ² test.
‡AMS1 vs C1.
§AMS2 vs C2.
¶AMS3 vs C3.
††Combined AMS vs combined non-AMS.
‡‡t test.

AMS=aggressive multiple sclerosis, defined as AMS1=Expanded Disability Status Scale (EDSS) 6 or greater reached within 5 years; AMS2=EDSS 6 or greater reached by age 40 years; AMS3=secondary progressive MS reached within 3 years of a relapsing-onset course; combined AMS=AMS1 and AMS2.

C=controls, defined as C1=not reached EDSS 6 or greater within 5 years from the onset of symptoms; C2=not reached EDSS 6 or greater by age 40 years with the onset of symptoms between 18 and 40 years; C3=not reached secondary progressive MS after 3 years of a relapsing-onset course; combined non-AMS=neither AMS1 nor AMS2, that is, not reached EDSS 6 or greater within 5 years from the onset of symptoms or by age 40 years (both criteria had to be fulfilled).

DMD=disease-modifying drug.

M5=multiple sclerosis.

N=aggressive multiple sclerosis+corresponding controls.
considered as they first came to clinic beyond 40 years of age and already had an EDSS score of 6 or greater at their first clinic visit. When compared to the source population, they were more likely to be male (257/786, 32.7% vs 1646/5891, 27.9%, \( p=0.003 \)), with an older onset age (36.8±11.0 vs 33.4±9.6 years, \( p<0.0001 \)) and have PPMS (227/786, 28.9% vs 589/5891, 10.0%, \( p<0.0001 \)).

AMS criterion (AMS1) — EDSS 6 or greater within 5 years
A total of 235 patients fulfilled this criterion and 4050 formed the corresponding non-aggressive comparator cohort (C1) — that is, those who had not reached EDSS 6 or greater within 5 years from the onset of MS symptoms. Therefore the aggressive cohort constituted 5.5% of the 4285 eligible patients (AMS1+C1). Patients with AMS were more likely to be male (\( p<0.0001 \)), older at MS onset (\( p<0.0001 \)) and have a PP disease course (\( p<0.0001 \)), compared to those without AMS (C1). The direction of findings was similar both before and after adjusting for other variables (see table 2 and figure 1).

AMS criterion (AMS2) — EDSS 6 or greater by age 40 years
A total of 388 patients fulfilled this criterion and 2374 formed the corresponding non-aggressive comparator cohort (C2) — that is, those who had not reached EDSS 6 or greater within 5 years from the onset of MS symptoms. Therefore the aggressive cohort constituted 14.0% of the total 2762 patients considered here (AMS2+C2). Compared to the control cohort (C2), those with AMS were more likely to be male, have PPMS and have a younger mean onset age (both before and after adjusting for other variables, \( p<0.0001 \)) (see table 2 and figure 1).

AMS criterion (AMS3) — SPMS within 3 years of a RO course
A total of 195 patients fulfilled this criterion and 4723 formed the corresponding non-aggressive comparator cohort (C3) — that is, those who had not reached SPMS after 3 years of a RO course. Therefore the aggressive cohort constituted 4.0% of the total 4918 (AMS3+C3) patients considered here. Patients with AMS were more likely to be male (\( p=0.0001 \)) and older at MS onset (\( p=0.0001 \)) when compared to those without AMS (C3) (both before and after adjusting for other variables; see table 2 and figure 1).

Combined AMS criteria (AMS 1 and 2)
A total of 523 unique patients satisfied at least one of the criteria (AMS 1 or AMS 2) for AMS and 3136 unique patients who satisfied neither of the criteria and had sufficient follow-up formed the combined non-aggressive comparator cohort. Therefore the combined AMS cohort constituted 14.3% of the total 3659 eligible patients. Patients in the combined AMS cohort were more likely to be male (\( p<0.0001 \)), younger at the onset of MS symptoms (\( p<0.0001 \)) and have a PP disease course (\( p<0.0001 \)) when compared to those without AMS (C3) (both before and after adjusting for other variables; see table 2 and figure 1).

Use of DMDs
Both the aggressive and comparator cohorts for the first two criteria included similar proportions of patients receiving a DMD at any point during follow-up (AMS1—41.7%, C1—40.5%, AMS2—38.1% and C2—39.2%). However for AMS3, 23.1% of AMS patients were ever exposed to a DMD compared to 41.0% in the corresponding non-AMS cohort (C3).
Sensitivity analysis
When extending the cut-off from 5 to 8 years for the criterion for AMS1, 477/3724 (12.8%) were considered as having AMS. As before, those with AMS were more likely to be male (176/477, 36.9% vs 852/3247, 26.2%, p<0.0001), older at MS onset (mean: 38.7±11.22 vs 31.7±8.59 years, p<0.0001) and present with PPMS (114/477, 23.9% vs 205/3247, 6.3%, p<0.0001).

Time to EDSS 8
Median time to EDSS 8 from the first EDSS score of ≥6 was similar across the three groups of patients with AMS (7.7, 8.0 and 8.6 years for AMS1, AMS2 and AMS3 cohorts, respectively; see figure 2).

DISCUSSION
We report on the occurrence and characteristics of patients with AMS in British Columbia, Canada. By exploring different individual definitions, we identified 4–14% of our patient population who could be considered as having AMS. We were able to find just one other study explicitly investigating AMS; this clinic-based study found 12.1% (n=59) of their cohort to have a ‘malignant’ status.12

We identified specific patient characteristics associated with the presence of AMS. Generally, men, those older at symptom onset and presenting with PPMS had higher odds of having AMS. These characteristics have typically been associated with a poorer outcome in previous natural history studies, albeit using different methodology and outcomes.27–31 However, it is of interest to note that despite these odds, around three out of every five patients identified as having AMS were women and the majority had RMS (typical of MS in general). Additionally by virtue of the ‘age at disability’ selection criteria for AMS2, these patients were younger at symptom onset.

There has been relatively little focus on creating a specific definition for AMS. In contrast, over 10 definitions for the other extreme disease presentation—benign MS—exist.32–34 The absence of an accepted definition for AMS likely explains the dearth of studies explicitly describing this extreme disease presentation. Aside from Lublin and Reingold’s descriptive definition of malignant MS,13 few have explored possible quantitative definitions. An early attempt in the 1970s to define...
Healthcare planners with an estimate of the prevalence of this disease is vital for robust clinical trial design, including the determination of sample size or study power. Second, it is necessary to have an estimate as to how many patients might be expected to present with this disease course. This type of information is valuable for designing clinical trials for new therapeutics by providing explicit criteria for AMS, along with an estimate as to how many patients would be eligible. Our study will possibly facilitate future studies on the treatments for AMS, including autologous haematopoietic stem cell therapy. Our findings could help in the design of clinical trials for new therapeutics by providing explicit criteria for AMS, along with an estimate as to how many patients might be expected to present with this disease course. This type of information is valuable for designing clinical trials for new therapeutics by providing explicit criteria for AMS, along with an estimate as to how many patients might be expected to present with this disease course. This type of information is vital for robust clinical trial design, including the determination of sample size or study power. Second, it is likely that patients with AMS are those most likely in urgent need of rehabilitation and palliative care services. Our study provides healthcare planners with an estimate of the prevalence of this type of MS disease course and the demographics of those affected. Lastly, by providing the much needed quantitative definitions for AMS, our study will possibly facilitate future studies investigating causation, susceptibility, expression or therapeutic interventions in this cohort of patients.

Strengths of our study include the population-based nature of the BCMS database, with an estimated 80% of the British Columbia MS population captured. Also, the patient follow-up in our study spans over 30 years and represents a significant natural history cohort.

Our study had some limitations. We had no information on the estimated 20% of patients not attending a BCMS clinic and thus not captured in the database. It is possible that patients with AMS lie in this 20%, particularly if a very rapid disease progression results in severe disability and perhaps institutionalisation even before patients gain access to an MS clinic. By definition, it is likely that not all potentially eligible patients had a chance of being selected for this study—for example, those with more than 5 years of disease duration at their first clinic visit could not be considered in AM51; however expanding this window in a sensitivity analysis resulted in largely similar findings. Also, a higher proportion of those excluded were older and had PPMS. It is possible that some of these patients would have been eligible; however how their inclusion might have affected findings is difficult to predict. Finally, we were unable to examine other potential important outcomes such as cognition, quality of life, employment or neuroimaging data, which would be useful to include in future studies.

In conclusion, using a combination of definitions we have identified from 1 in 25 up to 1 in 7 MS patients in British Columbia, Canada, as having AMS. Replication of findings in other longitudinal, largely natural history data sets would be of value. In addition, we hope that the data and findings presented stimulate further discussions and prompt the much needed creation of an internationally accepted consensus definition for AMS.

Acknowledgements We gratefully acknowledge the BC MS Clinic neurologists who contributed to the study through patient examination and data collection (current members listed here by primary clinic): UBC MS Clinic: A Traboulsee, MD, FRCP(C) (UBC Hospital MS Clinic Director and Acting Head of the UBC MS Programs); A-L Sayao, MD, FRCP(C) (Clinical Director of the BCMS Database); V Devonshire, MD, FRCP; S Hashimoto, MD, FRCP(C) (UBC and Victoria MS Clinics); J Hooe, MD, FRCP(C) (UBC and Prince George MS Clinic); L Kastrukoff, MD, FRCP(C) (CMC); Prince George MS Clinic: Matthew Adams, MD, FRCP(C); D Craig, MD, FRCP(C); S Meckling, MD, FRCP(C); Prince George MS Clinic: L Daly, MD, FRCP(C). Victoria MS Clinic: O Hrebicek, MD, FRCP(C); D Parton, MD, FRCP(C); K Atwell-Pope, MD, FRCP(C). We express our thanks in this paper do not necessarily reflect the views of each individual acknowledged. We thank T Duggan for his help in data coding.

Contributors SM: Study design, analysis and interpretation of data, drafting/revising the manuscript for content, including medical writing for content, statistical analysis, obtaining funding. AS: Revising the manuscript for content, including medical writing for content, interpretation of data, YZ: Revising the manuscript for content, including medical writing for content, statistical analysis, interpretation of data. MF: Revising the manuscript for content, including medical writing for content, interpretation of data. JO: Revising the manuscript for content, including medical writing for content, interpretation of data. AT: Revising the manuscript for content, including medical writing for content, interpretation of data. Funding Work carried out by the McDonald Fellowship (salary award) recipient from the Multiple Sclerosis International Federation.

Competing interests The British Columbia Multiple Sclerosis database has been funded via various grants over the years, including Canadian Institutes for Health Research (PI: HT), MS Society of Canada (PI: HT), National MS Society (PI: HT), the UBC MS/MRI Research Group and unrestricted grants from Dr Donald Paty. Suresh Menon is a recipient of the McDonald Fellowship from the Multiple Sclerosis International Federation. He has received travel awards/scholarships to present at conferences from the Consortium of MS Centres, Western Pacific endMS Regional Research and Training Centre and European Committee for the Treatment and Research in Multiple Sclerosis. Alfsaneh Shirani is funded through a postdoctoral fellowship from the Multiple Sclerosis Society of Canada, and grants from the Canadian Institutes for Health Research (FRN: 339878-MS-1197).
Multiple sclerosis

Canadian Institutes of Health Research (MOP-39646; Pt: HT) and the National Multiple Sclerosis Society (RG 42010-A-2; Pt: HT). She has received travel grants to present at and attend conferences from the endMS Research and Training Network (2010, 2011), the European Committee for Treatment and Research in Multiple Sclerosis (2010, 2011) and the Consortium of Multiple Sclerosis Centres (2012). Yinshan Zhao receives research funding from the National Multiple Sclerosis Society, the Canadian Institutes for Health Research and the Multiple Sclerosis Society of Canada. Joel Oger has received over the past 5 years speaker honoraria, consulting fees, travel grants and/or research grants and/or educational grants from Bayer, Biogen Idec, Genentech, Novartis, Serono, Shering, Talecis and Teva-neurosciences. He also receives fees for services from Bayer, Novartis and Biogen Idec to serve on advisory committees. Anthony Traboulsee received honorarium for membership on clinical trial steering committee for Roche and data safety monitoring board for Merck Serono. He received honorarium for presentations from EMD Serono, Biogen, Bayer and Sanofi Genzyme. Mark S Freedman—Receipt of research or educational grants: Bayer HealthCare, Genzyme. Receipt of honoraria or consultation fees: Actelion, Bayer HealthCare, Biogen Idec, Celgene, EMD Canada, Glycomed. Novartis, Sanofi-Aventis, Teva Canada Innovation. Member of a company advisory board, board of directors or other similar group: Actelion, Bayer HealthCare, Biogen Idec, Celgene, Glycomed, Merck Serono, Novartis, Sanofi-Aventis. Participation in a company sponsored speaker’s bureau: None. Helen Tremlett is funded by the Multiple Sclerosis Society of Canada (Don Paty Career Development Award) and Michael Smith Foundation for Health Research and is the Canada Research Chair for Neuropediatrics and Multiple Sclerosis. She has received research support from the US National Multiple Sclerosis Society, CIHR and UK MS Trust; speaker honoraria and/or travel expenses to attend conferences from the Consortium of MS Centres, US National MS Society, the University of British Columbia Multiple Sclerosis Research Program, Bayer Pharmaceutical (speaker, 2010, honoraria declined), Teva Pharmaceuticals (speaker, 2011), ECTRIMS (2011), UK MS Trust (2011), the Chesapeake Health Education Program, US Veterans Affairs (2012, honorarium declined) and Novartis Canada (2012). Unless otherwise stated, all speaker honoraria are either donated to an MS charity or to an unrestricted grant for use by her research group.

Ethics approval

The study was approved by the Clinical Research Ethics Board at the University of British Columbia which includes informed patient consent (study number: H11-01677).

Provenance and peer review

Not commissioned; externally peer reviewed.

REFERENCES